Ultragenyx Pharmaceutical Inc (RARE) was Reiterated by Wedbush to “Outperform” while Lowering the Price Target of the company shares to $ 92 from a previous price target of $99 . Wedbush advised their investors in a research report released on May 10, 2016.
Many Wall Street Analysts have commented on Ultragenyx Pharmaceutical Inc. Robert W. Baird Initiated Ultragenyx Pharmaceutical Inc on Mar 8, 2016 to “Outperform”, Price Target of the shares are set at $85.Leerink Partners Initiated Ultragenyx Pharmaceutical Inc on Feb 19, 2016 to “Outperform”, Price Target of the shares are set at $80.
On the company’s financial health, Ultragenyx Pharmaceutical Inc reported $-1.35 EPS for the quarter, missing the analyst consensus estimate by $ -0.12 based on the information available during the earnings call on May 9, 2016. Analyst had a consensus of $-1.23.During the same quarter in the previous year, the company posted $-0.63 EPS.
Ultragenyx Pharmaceutical Inc opened for trading at $61.61 and hit $64.85 on the upside on Friday, eventually ending the session at $63.16, with a gain of 1.14% or 0.71 points. The heightened volatility saw the trading volume jump to 4,80,812 shares. Company has a market cap of $2,462 M.
In a different news, on Apr 21, 2016, Sunil Agarwal (Chief Medical Officer) sold 649 shares at $70.53 per share price. According to the SEC, on Apr 19, 2016, Emil D Kakkis (President & CEO) sold 20,000 shares at $70.29 per share price. On Dec 18, 2015, Theodore Alan Huizenga (Controller and PAO) sold 1,500 shares at $110.55 per share price, according to the Form-4 filing with the securities and exchange commission.
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification acquisition development and commercialization of products for the treatment of rare and ultra-rare diseases with a focus on serious debilitating genetic diseases. Its pipeline consists of two product categories: biologics including a monoclonal antibody and enzyme replacement therapies and small-molecule substrate replacement therapies. Its products are KRN23 (UX023) rhGUS (UX003) rhPPCA (UX004) Triheptanoin (UX007) and SA-ER (UX001). KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. rhGUS is an intravenous (IV) enzyme replacement therapy for the treatment of mucopolysaccharidosis 7. rhPPCA is an enzyme replacement therapy for galactosialidosis. Triheptanoin is a medium odd-chain triglyceride of seven-carbon fatty acids. SA-ER is for the treatment of hereditary inclusion body myopathy (HIBM).